Proactive Investors - Run By Investors For Investors

Heritage Cannabis subsidiary adopts Voyage Cannabis as its new name

The company expects to be producing medical and recreational cannabis by the second quarter of 2019
Cannabis facility
Four greenhouses have already been built at its Falkland, British Columbia facilities

Heritage Cannabis Holdings Corp (CSE:CANN, OTCMKTS:HERTF) announced Monday that its subsidiary PhyeinMed Inc has changed its name to Voyage Cannabis Corp.

The newly named Voyage, which earned a Health Canada cultivation, processing and medical sales license, expects to be producing cannabis for medical and recreational use by the second quarter of 2019.

Shares of the Vancouver company jumped 1.6% to C$0.65 on the CSE and slipped 0.6% to US$0.48 on OTC Markets.

READ: Heritage Cannabis set to double extraction capacity in Ontario with two new orders

“The adoption of the Voyage name enhances the corporate imaging and supports a consistent brand within the company,” Heritage Chief Strategy Officer Debra Senger said in a statement. “We feel that the name Voyage will resonate with the consumer and will lend itself better to our future brand lines.”

The company is taking an individualized spin on medical cannabis, including working with BriteLife Sciences, to create personalized wellness brands that integrate cannabinoid into people’s daily lives.

Four greenhouses totalling 16,000 square feet have already been built at its Falkland, British Columbia facility. Additional greenhouses are expected in the future, whould would push the square footage to about 95,000.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CANN profile View Profile

Heritage Cannabis Timeline

Related Articles

1541165310_canadian-flag-1.jpg
November 02 2018
Back Home Medical Cannabis Corp has agreed on a 24,000-kilogram three-year production and supply agreement
Sydney Harbour Bridge
January 22 2019
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.
cannabis tablet
February 28 2019
The company fills a niche in the medicinal cannabis market, as it continues to push forward its suite of precision oral dose products
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use